Proteomics in bone malignancies: from bulk profiling to single-cell and ultra-low-input technologies
Jianming Chen, Jiaqiao Luo, Ning Ni, Jinhao Zhang, Lei Jiang, Hongbao Wu, Shenghao Wen, Ninghao Hu, Jiaran Li, Gang Deng, Shuxiang Song, Xiaomeng Shi · 2026
Read Proteomics in bone malignancies: from bulk profiling to single-cell and ultra-low-input technologies by Jianming Chen, Jiaqiao Luo, Ning Ni, Jinhao Zhang, Lei Jiang, Hongbao Wu, Shenghao Wen, Ninghao Hu, Jiaran Li, Gang Deng, Shuxiang Song, Xiaomeng Shi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13449687.txt.
Description
Jianming Chen and colleagues reviewed proteomics in bone cancers in 2026, moving from bulk tissue studies to single-cell and tiny-sample methods. Bone malignancies such as high-grade sarcomas spread early, vary greatly, and have seen little progress in drug treatment for relapsed disease. Gene and RNA data show only part of the picture, since proteins do the actual work of invasion and drug resistance.
The review synthesizes mass spectrometry studies, using osteosarcoma as the best-developed example, with Ewing sarcoma catching up at cohort scale. It covers protein abundance, signaling activity, and targets that might be drugged, while noting uneven evidence across tumor types. Researchers gain a guide to where proteomics is mature enough to use and where it remains early.
Catalog record
| CREATOR | Jianming Chen, Jiaqiao Luo, Ning Ni, Jinhao Zhang, Lei Jiang, Hongbao Wu, Shenghao Wen, Ninghao Hu, Jiaran Li, Gang Deng, Shuxiang Song, Xiaomeng Shi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 131 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |